Abstract: Slide Presentations |

Role of Ciprofloxacin as an Antitubercular Agent in Treatment of Pulmonary Tuberculosis FREE TO VIEW

Jai Kishan, MBBS; A. P. Kansal; Vikas Goyal
Author and Funding Information

TB & Chest Hospital, Patiala, India


Chest. 2003;124(4_MeetingAbstracts):107S. doi:10.1378/chest.124.4_MeetingAbstracts.107S-b
Text Size: A A A
Published online


PURPOSE:  Because of increased incidence of MDR-tuberculosis new antitubercular drugs need to be developed. We conducted study to see role of ciprofloxacin as antitubercular drug

METHODS:  100 freshly diagnosed sputum smear positive cases were randomly allocated into two groups of 50 patients each. Group A received RHZE cipro daily for first 2 months followed by RH daily for next 4 months.In Group B ciprofloxacin was omitted from above regimen. Results were analysed in terms of bacteriological, radiological and clinical criteria after 15, 30, 45 days, 2, 4, and 6 months of chemotherapy.

RESULTS:  In Group A 33 (66%), 45 (90%), 47 (94%) and 49 (98%) patients were sputum smear negative for acid fast bacilli after 15, 30, 45 days & 2 months of chemotherapy. The corresponding figure for Group B were 22 (44%), 36 (72%), 40 (80%) and 42 (84%) after 15, 30, 45 days, and 2 months of chemotherapy. The difference was statistically significant. Statistically there was no significant difference in sputum status among both the groups after 6 months of chemotherapy. Radiologically no difference was observed between two groups. In terms of clinical improvement in Group A showed significant improvement in relation to cough with expectoration and fever during first two months, but was leveled at 6 months. No significant difference among both the groups regarding adverse effects.CONCLUSIONS: Ciprofloxacin was found to have anti tubercular activity and resulted in faster sputum conversion rates after 15 days, 30 days, 45 days, and 2 months of chemotherapy.

CLINICAL IMPLICATIONS:  Ciprofloxacin can be used as an useful adjunct to the antitubercular drugs in areas of high prevalence of drug resistance in intensive phase and also in drug resistant cases.

DISCLOSURE:  J. Kishan, None.

Tuesday, October 28, 2003

12:30 PM - 2:00 PM




Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.

Find Similar Articles
CHEST Journal Articles
PubMed Articles
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543